Teva Pharmaceutical Industries Limited

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Technion Research & Development Foundation Ltd

Victor Piryatinsky

David Lerner

Yaacov Herzig

Avital Laxer

Istvan Miskolczi

Bronka Cohen

Dalia Pinkert

Hugo Gottlieb

Viktor Roschke

David William Lafleur

Marta Weinstock-Rosin

Hussein Hallak

Liora Sklair-Tavron

Moti Rosenstock

Liron Shemesh-Darvish

The subject invention provides deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, its salts and uses.

Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof

A method for treating an individual who has been identified as having Alzheimer's disease by administering orally to the individual a therapeutically effective amount of ladostigil or a pharmaceutically active salt thereof, wherein the therapeutically effective amount is 70 mg per day, 140 mg per day, or 200 mg per day. Also, a unit dosage form of ladostigil or a pharmaceutically active salt thereof in an amount of 50 mg, 70 mg, 80 mg or 100 mg.

Propargylated aminoindans, processes for preparation, and uses thereof

A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of cocaine exposure in the primate.

BChE albumin fusions for the treatment of cocaine abuse

This invention provides compounds having the structure: 

Growing community of inventors

Netanya, Israel

Victor Piryatinsky